Thomas Pierret 🫁

#ELCC26 KEYNOTE-671 non-pCR subgroup: EFS improved even without pCR 5-year EFS➡️42.9% vs 25.2% (31.9 vs 18.1 mOs; HR 0.69) Greatest benefit: – Squamous histology – PD-L1 ≥1% (especially ≥50%) More limited benefit: – Nonsquamous – PD-L1 <1%

Big implications, folks, for today's new reports on the thymus gland and healthspan —Our thymus gland largely involutes after the teenage years, but AI used to determine its persistent level of health —Healthy adult thymus linked to an array of remarkably improved health outcomes in 2 cohorts —Cardiovascular incidence and mortality reduced (Figure); also less all-cause mortality —Pulmonary mortality, digestive disease, metabolic disease mortality reduced (Figure) —Reduced inflammation; reduced lung cancer; improved metabolic markers nature.com/articles/s4158…

Beyond all of this, in a 2nd @Nature paper by the same team thymus, health associated with improved response to cancer immunotherapy @HugoAerts @simonbernatz and colleagues nature.com/articles/s4158…

Ahead of the European Lung Cancer Congress (ELCC) 2026, we asked leading AI models to forecast outcomes for high-impact lung cancer trials, before any numerical results are released. We compared predictions across models to generate an AI consensus on expected efficacy signals across NSCLC and ES-SCLC, covering key endpoints including PFS, OS, and EFS. Each forecast includes: hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, and a predicted Kaplan–Meier curve showing how outcomes may separate over time. Highlights: NSCLC HARMONi: Ivonescimab + chemotherapy projected strong PFS benefit ▶️ AI consensus PFS HR: 0.36 KEYNOTE-671: Perioperative pembrolizumab expected to sustain benefit at long-term follow-up ▶️ EFS HR: 0.59 | OS HR: 0.73 TOP: Osimertinib + chemotherapy predicted to improve outcomes vs osimertinib alone ▶️ PFS HR: 0.65 OptiTROP-Lung03: Sac-TMT projected to show meaningful OS benefit ▶️ OS HR: 0.59 ES-SCLC IMpower133: Long-term follow-up expected to maintain immunotherapy benefit ▶️ OS HR: 0.79 | PFS HR: 0.80 CAPSTONE-1: Adebrelimab + chemotherapy forecast to sustain survival advantage ▶️ OS HR: 0.76 Mixed signals EMPOWER-Lung 1: Cemiplimab monotherapy predicted to maintain durable survival gains ▶️ OS HR: 0.61 LATIFY: Limited benefit expected for ceralasertib + durvalumab ▶️ OS HR: 0.98 (not significant) Across trials, the AI consensus points to continued durability of immunotherapy benefits, incremental gains from combination strategies, and variable outcomes in targeted therapy settings. Which ELCC 2026 results do you expect will beat or fall short of these forecasts? Explore more insights and conference data from #ELCC26 👉 t.ly/ClEtq #LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @Tony_Calles | @FordePatrick | @HHorinouchi | @BalazsHalmosMD | @DrSanjayPopat

MTAP loss is frequent in oncogene-driven #NSCLC, with highest rates in ALK+ (up to 45%), followed by RET+ (up to 36%) and EGFR+ (up to 24%). IHC and NGS may be complementary for detection. #PRMT5i shows activity regardless of prior TKI exposure. PRMT5i + targeted therapy may outperform monotherapy in models with at least partial TKI sensitivity. @RETpositive @AlkPositive @EGFRResisters @DanaFarber @GustaveRoussy @Annals_Oncology

Emerging landscape of KRAS inhibitors in cancer treatment dlvr.it/TRSSmx

Results from ELIOS @CD_AACR: patients with EGFR mutant NSCLC had paired pre/post biopsies for NGS. At progression, most common acquired alterations were MET amp (17%), CDKN2A/B del (15%), MTAP (13%), C797S (13%). TROP2 expression independently high. aacrjournals.org/cancerdiscover…

Data on izalontamab brengitecan (iza-bren, EGFR-HER3 bispecific ADC) in AGA+ NSCLC (excluding common EGFR, reported separately) after standard treatment @JCO_ASCO. In EGFRex20 RR 69.2%, PFS 10.5m. HER2 RR 52.9%, PFS 7.5m. Only 1 case of ILD (G2). ascopubs.org/doi/10.1200/JC…

🚨 Check our Top 10 #LungCancer abstracts for ELCC 2026! We've hand-picked the must-see sessions with times & presenters. 🗓️ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link: lungsummit.org/elcc2026.ics Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer - Lung Cancer lungcancerjournal.info/article/S0169-…

🫁 FRONT-BRAF: ICI vs BRAF+MEK in BRAFV600E NSCLC. In metastatic BRAFV600E NSCLC (n=284), first-line ICI ± chemotherapy improved OS vs BRAF+MEK inhibitors: OS 40.9 vs 25.2 months HR 0.69 (0.49–0.98), p=0.039 Greater benefit in smokers, PD-L1 ≥1%, ≥70 years, TP53 co-mutation, no brain metastases. Retrospective design. Selection bias possible. Prospective validation needed. 📖 @TheLancetOncol DOI 👉🏻 10.1016/S1470-2045(25)00409-7 #CánCare #NSCLC #BRAF #Immunotherapy #ThoracicOncology #lcsm

🚨 FDA APPROVAL in 1L HER2-mutant NSCLC. Zongertinib receives accelerated approval based on Beamion LUNG-1 (single-arm, n=72): • ORR: 76% • Rapid responses (median 1.4 months) • 44% ≥12-month durability HER2 now officially joins the frontline targeted therapy era. @OncoAlert @MedwatchKate @OncoReporte @MedicalwatchHQ @FDAOncology

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.10…

5y outcomes from CheckMate 743 (1L nivolumab + ipilimumab vs chemo in mesothelioma) @JCO_ASCO. OS benefit with nivo/ipi persists: HR 0.74, 5y OS rates 14% vs 6% with benefit across histology. Important to see long term survival here - but need much more. ascopubs.org/doi/10.1200/JC…

Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) Full dose (80mg daily) Reduced dose(20-40mg daily) Dose-reduction increased risk of progression (primarily to the CNS) but did not affect OS. lungcancerjournal.info/article/S0169-…

Contemporary Management of Radiation Necrosis: Insights and Avenues in @CCR_AACR Radiation necrosis is not rare and may be rising in the immunotherapy era. 5–10% after conventional RT 5–9% after SRS Up to 23% in large lesions Up to 38% with SRS + ICI As survival improves, treatment related brain injury is emerging as a defining challenge in modern oncology aacrjournals.org/clincancerres/… @OncoAlert

🫁 ORCHARD: Osimertinib + Savolitinib in MET-Amplified EGFRm NSCLC. Post–1L osimertinib, MET amplification (n=32). ORR 47% (80% CI 34–60) mPFS 7.6 mo mDoR 14.5 mo mOS 20.7 mo G≥3 AEs 44% (pneumonia 9%). Single-arm, biomarker-selected cohort. 📖 @JTOonline DOI 👉🏻 10.1016/j.jtho.2025.10.009 #CánCare #NSCLC #EGFR #MET #TargetedTherapy #lcsm

🫁 Eficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors (DELII). Phase III, n = 500, pretreated solid tumors. Nivolumab 20 mg q2w vs docetaxel/paclitaxel. Median OS 5.88 vs 4.70 m, HR 0.80; P = .022, 1-year OS 27.3% vs 16.9% No PFS benefit. Grade ≥3 AEs 42.5% vs 60.8%. OS gain modest at 1.2 mo. No biomarker stratification. Dose de-escalation strategy ready for broader validation? 📖 @JCO_ASCO DOI 👉🏻 doi.org/10.1200/JCO-25… #CánCare #oncology #immunotherapy #ICI

TTF-1 negativity strongly correlated with worse outcomes to ICI monotherapy, chemo-immunotherapy, and durvalumab consolidation after concurrent chemoradiotherapy for stage III LUAD, even after accounting for potential confounders (including PD-L1, STK11, KEAP1, SMARCA4). 3/7

Biomarker complexity is rapidly increasing, yet the cost and accessibility of the technologies needed to implement them are not always keeping pace In @JTOonline, our comprehensive study of the routinely-assessed TTF-1 expression in lung adenocarcinoma jto.org/article/S1556-… 1/7